| Gene Name |
Pubmed ID |
Classification |
Sample Location |
Remark |
| DAPK1 | 17971771 | Methylation | VU University Medical Center in Amerstdam | DAPK1 is significantly methylated with frequency 56.3% in squamous cell carcinomas. |
| DAPK1 | 17548682 | Methylation | University of Dakar, Senegal | DAPK1 is hypermethylated and thus it can be a potential and a sensitive molecular marker in urine sample from cervical cancer patients. DAPK1 is more methylated in 49% of ICC and 28% of CIN2-3/CIS. |
| DAPK1 | 15713962 | Methylation | Community Health Clinic in Dakar, Senegal. | The frequency of hypermethylation of DAPK1 increased statistically significantly with increasing severity of neoplasia present in the cervical biopsy (P<0.001) |
| DAPK1 | 12773202 | Methylation | Instituto Nacional de Cancerologia, Colombia and Department of Obstetrics and Gynecology of Friedrich Schiller University, Jena, Germany | The frequency of methylation of DAPK1 gene promoter is 43.3%. |
| DAPK1 | 20208141 | Methylation | Pathology Archives of the University Medical Center Groningen (UMCG). | Methylation of DAPK1 increases during cervical carcinogenesis and thus is reported as one of the best markers to distinguish normal/LSIL from HSIL/cancer lesions. |
| DAPK1 | 16331610 | Methylation | Gynecologic Oncology Division of Seoul National University Hospital | Methylation of DAPK gene is more frequently in AC than SCC (77.4%,P=0.005) |
| DAPK1 | 19513524 | Methylation | Colposcopy Unit of University Hospital of Larissa; Greece. | DAPK promoter methylation has been found in 66.7% of premalignant and 57.4% of cancer cases. |
| DAPK1 | 14760078 | Methylation | Department of Obsterics and Gynecology, Innsbruck University Hospital. | Aberrant methylation of CpG island within the promoter regions. |
| DAPK1 | 11448914 | Methylation | Samsung Cheil Hospital, Seoul, Korea | DAPK is significantly more methylated with frequency 61% in squamous cell carcinoma |
| DAPK1 | 12702579 | Methylation | Anatomical Pathology Department of the City of Hope National Medical Center. | Aberrant methylation of CpG island within the promoter regions has been observed in the 25-50% of the tumors. |
| DAPK1 | 16736496 | Methylation | Clinic of the University Medical Center Groningen. | DAPK promoter methylation was significantly more methylated in cancers than control |
| DAPK1 | 19836067 | Methylation | Chonnam National University Hwasun Hospital | The trend of methylation of this gene is increasing with increasing severity of cervical squamous lesions (p<0.001). |
| DAPK1 | 15589597 | Methylation | Department of Obstertics and Gynecology, Seoul national University Hospital. | Frequency of methylation of this gene is found to be 73.2%. |
| DAPK1 | 18181097 | Methylation | Johns Hopkins Hospital. | Methylation of this gene was detected in 10 (25.6%) of 39 HSIL Pap tests compared with 2(3.3%) of 60 combined NILM/LSIL Pap tests. |
| DAPK1 | 16803511 | Methylation | Busan Paik Hospital, Inje University, Busan, South Korea. | The frequencies of promoter methylation of p16, DAPK, CDH1, and TIMP-3 in cervical cancer were 57%, 44.9%, 52.6%, and 9%, respectively |
| DAPK1 | 16928264 | Methylation | - | Incidence of hypermethylation for DAPK, MGMT, p16 and PTEN in cervical cancer was 56.7%, 25.2%, 16.5% and 15.7% respectivel |
| DAPK1 | 15099958 | Methylation | Queen Mary Hospital, Hong Kong. | Promotor CpG island methylation of DAPK, p16, and MGMT was detectable, respectively, in 60%, 28.2%, and 18.8% of cases of cervical tumor DNA, and in 40%, 10%, and 7.5% of cases of patients' plasma DNA |
| DAPK1 | 14767518 | Methylation | - | reduced DAPK expression and methylation of the DAPK promoter may be involved in carcinogenesis of human uterine and ovarian tissues. |
| DAPK1 | 19755648 | Methylation | Coloscopy Clinic, Jessop Wing or the Oncology Department of the Royal hallamshire Hospital, Sheffield. | Tumor suppressor gene DAPK exhibited a significantly increased frequency of promoter methylation with progressively more severe cervical neoplasia (P < 0.05). HIC1 gene is reported to be a potential biomarker of cervical neoplasia |